Rafferty Asset Management LLC Reduces Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Rafferty Asset Management LLC cut its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 20.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 109,236 shares of the biotechnology company's stock after selling 28,806 shares during the quarter. Rafferty Asset Management LLC owned about 0.11% of Sarepta Therapeutics worth $13,282,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in SRPT. Park Avenue Securities LLC purchased a new position in shares of Sarepta Therapeutics in the fourth quarter valued at $205,000. Smith Salley Wealth Management purchased a new position in shares of Sarepta Therapeutics in the fourth quarter valued at $889,000. UMB Bank n.a. grew its position in shares of Sarepta Therapeutics by 36.0% in the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after purchasing an additional 138 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 156 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Sarepta Therapeutics by 23.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,317 shares of the biotechnology company's stock worth $160,000 after buying an additional 247 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Stock Up 5.4%

SRPT stock traded up $2.05 on Tuesday, reaching $39.99. 4,909,209 shares of the company traded hands, compared to its average volume of 1,736,703. Sarepta Therapeutics, Inc. has a one year low of $34.10 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company has a market cap of $3.93 billion, a P/E ratio of 31.99 and a beta of 0.85. The firm has a fifty day simple moving average of $58.87 and a 200-day simple moving average of $96.59.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. During the same period last year, the business earned $0.73 EPS. The firm's quarterly revenue was up 80.2% on a year-over-year basis. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

SRPT has been the topic of a number of research analyst reports. Oppenheimer decreased their target price on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright decreased their target price on Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. The Goldman Sachs Group decreased their target price on Sarepta Therapeutics from $178.00 to $100.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Evercore ISI lowered Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 target price on the stock. in a research note on Thursday, May 8th. Finally, Guggenheim decreased their target price on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $122.61.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.